ARS Pharmaceuticals, Inc. - Common Stock SPRY 深 沪
已收盘 12-24 16:00:00 美东时间
11.48
+0.450
+4.08%
华盛通- 最 高11.685
- 今 开11.09
- 成交量 98.54万股
- 最 低 10.96
- 昨 收 11.03
- 总市值 11.35亿
- 52周最高 18.90
- 市盈率 静 146.99
- 换手率 0.00%
- 52周最低 6.66
- 委 比 -66.17%
- 总股本 9882.63万
- 历史最高 63.41
- 量 比 0.59
- 振 幅 6.57%
- 历史最低 2.55
- 每 手 1
- 风险率 2.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
ARS Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference in New York from Dec 2-4, 2025. Co-Founder Richard Lowenthal and Chief Commercial Officer Eric Karas will engage in a fireside chat with analyst David Amsellem on Dec 3 at 2:30 pm ET. The event will be webcast live and available for 90 days on the Company’s website. The biopharmaceutical company specializes in producing neffy®, an epinephrine nasal spray f...
11-26 13:00
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.17 percent. This is a 160 percent decrease over losses of $(0.20) per share
11-10 19:00
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
11-08 02:04
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
ARS Pharma will present one late-breaking oral and six poster presentations at the 2025 ACAAI Annual Meeting, highlighting real-world data on the effectiveness of neffy® (epinephrine nasal spray) for treating anaphylaxis. Data shows that 90% of patients experienced successful treatment with a single dose. Presentations cover diverse patient experiences, including use during oral food challenges and allergy immunotherapy. neffy® is also shown to b...
11-03 12:45
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Spyre Therapeutics, a clinical-stage biotech company focused on treating inflammatory bowel disease and other immune-mediated conditions, announce the closing of its underwritten public offering. The company sold 17,094,594 shares, including 2,229,729 additional shares due to underwriters' option exercise, at $18.50 per share, resulting in approximately $316.2 million in gross proceeds. Jefferies, TD Securities, Leerink Partners, and Stifel acted...
10-15 20:15
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
ARS Pharmaceuticals announced that the European Patent Office upheld the validity of its nasal spray epinephrine formulation patent in over 30 European countries. Earlier, the U.S. Patent and Trademark Office also upheld a related U.S. patent for treating type-1 hypersensitivity reactions, including anaphylaxis. The company's patents, covering its product **neffy®**, provide protection until at least 2039. **neffy®** is a nasal spray used for eme...
10-08 12:00
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics granted stock options to purchase 42,500 shares to three non-executive employees under its 2018 Equity Inducement Plan. The options, approved on October 1, 2025, have an exercise price of $16.46, vesting over 10 years with 1/4 of shares vesting after the first year and monthly vesting of 1/48 thereafter, contingent on continued employment. The company focuses on developing therapies for inflammatory bowel disease and other immu...
10-03 20:05
ARS Pharmaceuticals Secures $250 Million Credit Agreement
ARS Pharmaceuticals ( ($SPRY) ) has provided an announcement. On September 29, ...
09-30 04:51
ARS Pharma secures $250M loan to accelerate Neffy rollout
ARS Pharmaceuticals (NASDAQ:SPRY) announced a $250M senior secured term loan with affiliates of RA Capital and OMERS Life Sciences. An initial $100M draw will support the commercial expansion of neffy...
09-30 04:19
